Table 1.
Clinical findings of patients with rheumatoid arthritis who developed methotrexate‐associated lymphoproliferative disorders, compared between diffuse large B‐cell lymphoma‐type and classical Hodgkin lymphoma‐type
| All patients (n = 51) | DLBCL‐type (n = 34) | CHL‐type (n = 17) | P‐value | |
|---|---|---|---|---|
| Age | 67 (45–84) | 70 (55–82) | 64 (45–84) | 0.09 |
| Sex (male:female) | 14:37 | 10:24 | 4:13 | 0.46 |
| PS ≥ 2 | 37% (17/46) | 41% (12/29) | 29% (5/17) | 0.46 |
| Clinical stage ≥3 | 75% (38/51) | 74% (25/34) | 76% (13/17) | 0.55 |
| High LDH levels | 67% (33/49) | 72% (23/32) | 59% (10/17) | 0.37 |
| Extranodal disease | 57% (29/51) | 65% (22/34) | 41% (7/17) | 0.10 |
| Extranodal disease ≥2 | 8 | 5 | 3 | 0.76 |
| B symptom positive | 53% (24/45) | 57% (17/30) | 47% (7/15) | 0.38 |
| EBER positive | 82% (42/51) | 82% (28/34) | 82% (14/17) | 0.66 |
| Died | 6 | 5 | 1 |
High lactate dehydrogenase (LDH) levels were defined as values equal to or greater than the reference value. DLBCL, diffuse large B‐cell lymphoma; CHL, classical Hodgkin lymphoma; EBER, Epstein‐Barr Virus‐encoded small RNA in situ hybridization; MTX, methotrexate; PS, Eastern Cooperative Oncology Group performance status.